Literature DB >> 8401995

A quantitative ELISA for measurement of rheumatoid factor associated cross-reactive idiotypes in serum from patients with rheumatic diseases.

F Shokri1, R A Mageed, R Jefferis.   

Abstract

A sensitive ELISA for the quantitation of RF associated cross-reactive idiotypes (CRI) has been developed. CRI bearing IgM was captured by immobilized F(ab')2 fragments of monoclonal anti-CRI antibodies and revealed with isotype specific conjugates. Factors affecting sensitivity, specificity and reproducibility of the assay were assessed. The sensitivity limit was less than 10 ng/ml and the linear assay range for the CRI standard curve was from 80 to 500 ng/ml. Using this ELISA system we have quantitated serum levels of the CRI in different groups of patients with RA, early synovitis and normal individuals. Our results indicate a significant increase in the levels of the CRI in the patient groups compared to the normal subjects tested, and suggest involvement of a diverse repertoire of Ig variable region germline genes and/or somatic mutation in production of polyclonal RF in RA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8401995     DOI: 10.1093/rheumatology/32.10.862

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  3 in total

1.  Increased IgA rheumatoid factor and V(H)1 associated cross reactive idiotype expression in patients with Lyme arthritis and neuroborreliosis.

Authors:  J S Axford; D H Rees; R A Mageed; P Wordsworth; A Alavi; A C Steere
Journal:  Ann Rheum Dis       Date:  1999-12       Impact factor: 19.103

2.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia, multiple myeloma and chronic lymphocytic leukemia.

Authors:  S Gharagozloo; J Khoshnoodi; F Shokri
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma.

Authors:  S Gharagozloo; R A Sharifian; R A Mageed; F Shokri
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.